Advanced Breast Cancer

Oncology·MeSH: Breast Neoplasms

Prevalence

287.0 / 100K

Incidence

128.0 / 100K/yr

17 drugs in development·7 companies·23 clinical trials

Drug Pipeline by Phase

Approved(1)

Drug	Company
theralink assay for breast cancer	THERALINK TECHNOLOGIES, INC. (THER)

Phase 3(5)

Drug	Company
Atirmociclib	ASTRAZENECA PLC (AZN)
Camizestrant	ASTRAZENECA PLC (AZN)
Giredestrant	ENANTA PHARMACEUTICALS INC (ENTA)
GnRH Agonist	ENANTA PHARMACEUTICALS INC (ENTA)
LHRH Agonist	ENANTA PHARMACEUTICALS INC (ENTA)

Phase 2(7)

Phase 1(3)

Drug	Company
ARV-471	PFIZER INC (PFE)
elacestrant	STEMLINE THERAPEUTICS INC (STML)
men2312	STEMLINE THERAPEUTICS INC (STML)

Phase 1/Phase 2(1)

Drug	Company
bnt323	BioNTech SE (BNTX)

BioSniper tracks 17 drugs in development for Advanced Breast Cancer across 7 companies.

There are 23 clinical trials targeting Advanced Breast Cancer tracked by BioSniper.

The estimated prevalence of Advanced Breast Cancer is approximately 287.0 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.